SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th

Company Overview - SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [5] - The company's first commercial product, QUELIMMUNE (SCD-PED), was approved by the U.S. FDA in 2024 and is the only FDA-approved product for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [5] - SeaStar's Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for four therapeutic indications by the FDA, facilitating a faster approval process and better reimbursement dynamics [5] Recent Developments - SeaStar Medical announced the publication of positive safety and patient outcomes data from the SAVE Surveillance Registry in pediatric patients treated with QUELIMMUNE in the journal Pediatric Nephrology [9] - The company is currently enrolling patients in the pivotal NEUTRALIZE-AKI clinical trial, evaluating the safety and efficacy of SCD therapy in adults with AKI in the ICU [9] - SeaStar has initiated the NEUTRALIZE-CRS clinical trial to treat patients with acute chronic systolic heart failure with cardiorenal syndrome (CRS) [9] Upcoming Events - Eric Schlorff, CEO of SeaStar Medical, will participate in a fireside chat at the Life Sciences Investor Forum on March 11, 2026 [1] - The event will be an interactive online forum allowing real-time questions from investors and industry professionals [2]